Surpassing $1 billion in annual sales marks a major milestone for any biopharmaceutical company, and Acadia Pharmaceuticals (ACAD) is steadily moving toward that goal. Driven by continued commercial growth across its key products and expanding market opportunities, the company is positioning itself for its next phase of long-term success.
Acadia is focused on developing drugs for underserved neurological and rare disease communities around the world. Its commercial portfolio includes Nuplazid, the first and only FDA-approved therapy for Parkinson's disease psychosis, and Daybue, the first approved treatment for Rett syndrome.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.